- Current report filing (8-K)
03 Fevereiro 2009 - 8:06PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported):
February 3,
2009
ALLOS THERAPEUTICS, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
000-29815
|
|
54-1655029
|
(State
or other jurisdiction
|
|
(Commission
|
|
(IRS
Employer
|
of
incorporation)
|
|
File
Number)
|
|
Identification
No.)
|
11080 CirclePoint Road, Suite 200
Westminster, Colorado
|
|
80020
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrants
telephone number, including area code:
(303)
426-6262
Not applicable
(Former
name or former address, if changed since last report.)
Check the appropriate box
below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see
General Instruction A.2. below):
o
Written communications pursuant to Rule 425
under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12
under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Section 8 Other Events
Item 8.01 Other
Events.
On February 3, 2009,
Allos Therapeutics, Inc., a Delaware corporation (the Company), issued a
press release
announcing the final results from the Companys pivotal
Phase 2 PROPEL trial of pralatrexate in patients with relapsed or refractory
peripheral T-cell lymphoma. The press release is attached hereto
as Exhibit 99.1 and incorporated herein by reference.
Section 9 Financial Statements and Exhibits
Item 9.01 Financial
Statements and Exhibits.
(d) Exhibits
99.1
|
|
Press
Release, dated February 3, 2009, entitled Allos Therapeutics Announces
Final Results From Pivotal Propel Trial Of Pralatrexate In Patients With
Peripheral T-Cell Lymphoma.
|
2
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Dated: February 3, 2009
|
|
ALLOS
THERAPEUTICS, INC.
|
|
|
|
|
|
|
|
By:
|
/s/
Marc H. Graboyes
|
|
|
Marc
H. Graboyes
|
|
Its:
|
Senior
Vice President, General Counsel and Secretary
|
3
EXHIBIT INDEX
Exhibit No.
|
|
Description
|
|
|
|
99.1
|
|
Press
Release, dated February 3, 2009, entitled Allos Therapeutics Announces
Final Results From Pivotal Propel Trial Of Pralatrexate In Patients With
Peripheral T-Cell Lymphoma.
|
4
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024
Allos Therapeutics, Inc. (MM) (NASDAQ:ALTH)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024